Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,303 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Mezigdomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • New Haven, Connecticut • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Dysphagia Using the Mendelsohn Maneuver

NCT00592761
View directory record Official record
Conditions
Stroke, Dysphagia
Interventions
Mendelsohn Maneuver
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 16, 2026, 1:03 AM EDT
Withdrawn Phase 1 Interventional

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07082270
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Questionnaire Administration, Selvigaltin
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional Results available

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions
AMG 176, Azacitidine, Itraconazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

NCT01113515
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Esmolol hydrochloride, Placebo gel
Drug
Lead sponsor
Novalead Pharma Private Limited
Industry
Eligibility
18 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 16, 2026, 1:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Value of Community Vital Signs in Primary Care

NCT02512835
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Cardiovascular Disease
Interventions
Community vital signs
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 16, 2026, 1:03 AM EDT
Completed No phase listed Observational

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT01675440
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 1:03 AM EDT
Not listed Not applicable Interventional

Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation

NCT03869879
View directory record Official record
Conditions
Parkinson Disease, Stroke, Multiple Sclerosis, Gait Disorders, Neurologic, Gait Disorder, Sensorimotor, Gait, Unsteady, Gait Ataxia, Gait, Stumbling, Gait, Shuffling
Interventions
Feedback-assisted physical therapy, Traditional physical therapy
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salem, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 16, 2026, 1:03 AM EDT
Active, not recruiting Not applicable Interventional

BioVentrix Revivent TC™ System Clinical Study

NCT02931240
View directory record Official record
Conditions
Ventricular Dysfunction, Left
Interventions
Revivent TC
Device
Lead sponsor
BioVentrix
Industry
Eligibility
18 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 16, 2026, 1:03 AM EDT
Recruiting No phase listed Observational

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

NCT06649097
View directory record Official record
Conditions
Intracranial Hemorrhage, Ventriculitis, Intracranial Abscess
Interventions
IRRAflow® CNS (Active Fluid Exchange) System
Device
Lead sponsor
Christopher P Kellner
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 16, 2026, 1:03 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Phased Radio Frequency Ablation System

NCT01693120
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Medtronic Phased RF Ablation System
Device
Lead sponsor
Medtronic Cardiac Ablation Solutions
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 16, 2026, 1:03 AM EDT
Completed No phase listed Observational Results available

RAAS and Arterial Stiffness in SCI

NCT04510974
View directory record Official record
Conditions
Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury, Hypotension
Interventions
Spinal Cord Injury
Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Enrollment
33 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 2Phase 3 Interventional

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

NCT05070260
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo
Drug
Lead sponsor
Acticor Biotech
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Bradenton, Florida • St. Petersburg, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

NCT01282424
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
Interventions
Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
22
States / cities
Fullerton, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

NCT05953480
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Redasemtide, Placebo
Biological · Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Pivotal Study of a Percutaneous Mitral Valve Repair System

NCT00209274
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
Percutaneous mitral valve repair using MitraClip implant, Mitral valve repair or replacement surgery
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Not applicable Interventional

The Effects of Plantar Flexion Training in People With Chronic Stroke

NCT03548090
View directory record Official record
Conditions
Stroke, Hemiplegic Gait
Interventions
Skateboard exercise at an incline angle of 0 degrees and 50% body weight, Skateboard exercise at an incline angle of 5 degrees and 50% body weight, Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight, Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight, Control 4-week exercise intervention, Experimental 4-week exercise intervention, Over-ground multi-directional gait training, Home exercise
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

NCT01958320
View directory record Official record
Conditions
Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
Interventions
pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Days to 14 Days
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • San Jose, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 16, 2026, 1:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT03401788
View directory record Official record
Conditions
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
Interventions
Belzutifan
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 1:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Erythromycin in GER-Associated Apnea of the Newborn

NCT01825473
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia
Interventions
Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Days and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 16, 2026, 1:03 AM EDT
Approved For Marketing No phase listed Expanded access

Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissections

NCT02464943
View directory record Official record
Conditions
Aortic Dissection
Interventions
Endovascular Treatment (Zenith)
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Camden, New Jersey • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 16, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

NCT04739059
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 1:03 AM EDT